No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
INSM240517P20000
- 0.30
- +0.05+20.00%
15min DelayClose May 8 15:59 ET
0.30High0.25Low
0.25Open0.25Pre Close11 Volume501 Open Interest20.00Strike Price315.00Turnover142.90%IV-24.23%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.30Time Value100Contract SizeAmericanOptions Type-0.0989Delta0.0299Gamma86.67Leverage Ratio-0.0554Theta-0.0007Rho-8.57Eff Leverage0.0071Vega
Intraday
- 5D
- 1D
News
Insmed To Present at the BofA Securities Health Care Conference 2024
We Think Some Shareholders May Hesitate To Increase Insmed Incorporated's (NASDAQ:INSM) CEO Compensation
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Express News | Insmed Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $48
Insmed Initiated at Buy by Truist Securities
Insmed Initiated at Buy by Truist Securities
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
Comments
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The Wells Fargo equity team identified 14 high-conviction, catalyst-driven stock opportunities for the second quarter, including two Magnificent 7 names: Amazon and Tesla.
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
10
1
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Insiders at Insmed selling shares may indicate they believe the shares are overpriced. Some alignment exists between management and smaller shareholders, but lack of recent insider buying and net selling over the past year raises concerns.
1
Insmed's overvaluation and slower than average forecasted revenue growth raise investors' concern. Despite hopes for a turnaround, analysts express less confidence, indicating risks for shareholders and potential investors.
Read more